priors.science/reviews/acute-coronary-syndrome-management

Acute Coronary Syndrome Management

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
143primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
2 Established · 9 Likely · 8 Uncertain · 1 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Fondaparinux reduces major bleeding versus enoxaparin in NSTE-ACSAnticoagulationEstablished88%8
High-intensity statins reduce MACE in acute coronary syndrome patientsLipid LoweringEstablished85%11
PCSK9 inhibitors added to statins reduce MACE post-ACSPcsk9 InhibitionLong-standingLikely81%9
ACE inhibitors reduce mortality in ACS with reduced ejection fractionRaas BlockadeLong-standingLikely80%8
Major bleeding post-ACS independently predicts 30-day mortalityAnticoagulationLikely79%6
Ezetimibe added to statins reduces cardiovascular events post-ACSLipid LoweringLikely78%8
Beta-blockers reduce mortality in ACS with reduced ejection fractionBeta Blocker TherapyLikely77%8
Exercise-based cardiac rehabilitation reduces cardiovascular mortality post-MICardiac RehabilitationLikely77%9
Complete revascularization reduces MACE versus incomplete in multivessel ACSRevascularizationLikely72%10
Exercise-based cardiac rehabilitation reduces reinfarction risk post-MICardiac RehabilitationLikely70%6
P2Y12 monotherapy after short DAPT reduces bleeding without increasing MACEAntiplatelet TherapyLikely70%10
DAPT de-escalation to clopidogrel is non-inferior for MACE post-ACSAntiplatelet TherapyUncertain69%10
Colchicine reduces MACE after myocardial infarctionAnti InflammatoryUncertain68%10
Potent P2Y12 inhibitors reduce MACE versus clopidogrel post-ACSAntiplatelet TherapyUncertain68%11
CABG reduces long-term mortality versus PCI in multivessel ACSRevascularizationUncertain60%8
SGLT2 inhibitors reduce heart failure hospitalization post-ACSSglt2 InhibitionUncertain53%8
Beta-blockers lack mortality benefit in ACS with preserved ejection fractionBeta Blocker TherapyEarly evidenceUncertain52%8
RAAS blockade provides no clear mortality benefit in ACS with preserved ejection fractionRaas BlockadeUncertain51%5
FFR-guided PCI and CABG have similar outcomes in multivessel NSTE-ACSRevascularizationUncertain51%5
SGLT2 inhibitors benefit post-ACS patients without diabetesSglt2 InhibitionDoubtful46%6
Track Acute Coronary Syndrome Management.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Early evidenceMost of this evidence is from the last two years.
Long-standingMost of this evidence is older than the rest of this field.